Learn More about Lumida ETF
Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home Lifestyle Health and Longevity

America’s Fertility Rate Just Hit a Record Low — and the Numbers Are Getting Harder to Ignore

by Team Lumida
April 10, 2026
in Health and Longevity
Reading Time: 3 mins read
A A
0
America’s Fertility Rate Just Hit a Record Low — and the Numbers Are Getting Harder to Ignore
Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp
  • The U.S. general fertility rate fell to a record low of 53.1 births per 1,000 women ages 15–44 in 2025, according to provisional CDC data — continuing a decline that began in 2007 and has now persisted through six straight years of flat births (~3.6 million annually)
  • The total fertility rate — the average number of children a woman would have over her lifetime at current rates — dropped to 1.57 in 2025, well below the 2.1 replacement level; the U.S. population will eventually shrink without sustained immigration if this trend continues
  • For the first time in U.S. history, birthrates for women in their late 30s exceeded those for women in their early 20s — a structural shift reflecting delayed parenthood driven by financial uncertainty, relationship instability, and political climate concerns
  • The teen birthrate fell 7% in 2025, extending a decades-long decline; since 2007, the birthrate for 15–19-year-olds has fallen 72%, while births over deaths now produce only a half-million net surplus annually — a surplus Census projects will disappear within a decade

What Happened?

New federal data from the CDC shows that America’s fertility rate fell to a record low in 2025 for the sixth consecutive year of flat total births. The general fertility rate — births per 1,000 women ages 15 to 44 — reached 53.1, its lowest point on record. The total fertility rate dropped to 1.57 births per woman, a WSJ calculation shows, significantly below the 2.1 replacement level required for a population to sustain itself without immigration. A historic milestone was crossed in 2025: for the first time, birthrates for women in their late 30s exceeded those of women in their early 20s, reflecting the long-running shift toward delayed parenthood across generations of American women.

Why It Matters?

The fertility decline is not merely a demographic abstraction — it has direct implications for the U.S. economy, retirement systems, and the labor force over the next two to three decades. Flat births and a rising number of deaths are already shrinking the natural population surplus: the U.S. recorded just over 500,000 more births than deaths in 2025. Census Bureau and CBO projections suggest this surplus will disappear within the next decade. After that, population growth — and with it, the labor force, tax base, and economic dynamism that underpin Social Security and Medicare — will depend entirely on immigration. Demographers note that many women still want children but are waiting until financial and relational conditions feel stable enough, suggesting the gap between desired and actual fertility is structural and policy-amenable, not purely cultural.

What’s Next?

The U.S. fertility rate, while at a record low, remains higher than in many other developed nations — the UN estimates more than half of all countries are already below replacement level globally. But the gap is narrowing, and the U.S. no longer has a meaningful demographic edge over peers. Policy levers that other countries have tried — paid family leave, childcare subsidies, child tax credits — have produced mixed results in shifting fertility rates. The more immediate policy question is immigration: the same restrictionist impulses that have driven recent U.S. immigration enforcement could, if sustained, eliminate the demographic safety valve just as natural population growth runs out. How Washington navigates that tension over the next decade may be one of the most consequential long-run policy choices the country faces.

Source: The Wall Street Journal

Previous Post

Anthropic’s New AI Model Is So Dangerous Bessent and Powell Called an Emergency Meeting With Bank CEOs

Next Post

The ‘Busan Freeze’: How Trump Quietly Abandoned His Tough-on-China Playbook

Recommended For You

Healthcare Roundup: Medicare Advantage Gets a $13B Boost, Drug Tariffs Hit 100%, and Wegovy Goes Discount

by Team Lumida
23 hours ago
person sitting while using laptop computer and green stethoscope near

A packed week in healthcare: Medicare Advantage rates came in at a better-than-expected 2.48% increase, Trump unveiled 100% tariffs on some brand-name drugs, Gilead and Neurocrine spent $8B...

Read more

Why Americans Pay More for Healthcare Than Anyone Else in the World

by Team Lumida
3 days ago
doctor holding red stethoscope

A new WSJ analysis breaks down the structural forces behind America's sky-high healthcare costs — from monopoly hospitals and unregulated drug prices to administrative bloat and physician salaries...

Read more

Genetic Tests Come Under Federal Scrutiny as Trump Administration Targets Lab Fraud

by Team Lumida
4 days ago
Supreme Court Signals It Will Strike Down Trump’s Birthright Citizenship Order

The CMS has opened a public comment period on how to curb fraudulent genetic testing billing — a billion-dollar problem involving unnecessary tests marketed directly to consumers and...

Read more

94% of Physicians Have Adopted or Want AI — But Accuracy Concerns Remain the Top Barrier

by Team Lumida
1 week ago
a man holding a ball in his right hand

A Doximity survey of more than 3,000 physicians finds that AI adoption in clinical practice has surged from 47% to 63% in under a year — but more...

Read more

Up to 10 Million Americans Could Lose Medicaid by 2028 Under New Work Requirements

by Team Lumida
1 week ago

A new Urban Institute and Robert Wood Johnson Foundation analysis finds that 5 to 10 million people could be disenrolled from Medicaid in 2028 due to work requirements...

Read more

One-Third of Americans Now Use AI for Health Advice — and Many Are Skipping the Doctor

by Team Lumida
1 week ago
One-Third of Americans Now Use AI for Health Advice — and Many Are Skipping the Doctor

A KFF poll of 1,300+ U.S. adults finds roughly 1 in 3 now use AI for health information — as often as social media — with 40%+ uploading...

Read more

The Weight Loss Drug Race: What’s Available Now and What’s Coming Next

by Team Lumida
2 weeks ago
The Weight Loss Drug Race: What’s Available Now and What’s Coming Next

The obesity drug market is set for a major expansion, with Eli Lilly's once-daily pill targeting April FDA approval, Novo Nordisk launching a high-dose shot, and six additional...

Read more

GLP-1s Aren’t a Shortcut. They’re a Powerful Tool That Still Needs a Real Health Strategy

by Team Lumida
2 weeks ago
GLP-1s Aren’t a Shortcut. They’re a Powerful Tool That Still Needs a Real Health Strategy

Key Takeaways Powered by lumidawealth.com GLP-1 drugs can be highly effective for weight management, but they work best when combined with diet, physical activity, and clinical follow-up. The bigger...

Read more

Sleep Regularity Is the Underrated Health Lever Most People Miss

by Team Lumida
3 weeks ago
woman sleeping on bed under blankets

Key Takeaways Powered by lumidawealth.com A consistent sleep and wake time may be one of the simplest high-impact health habits. Healthy sleep is not just about hours. Regular timing...

Read more

Generic Ozempic Wave Could Redraw the Global GLP-1 Market

by Team Lumida
3 weeks ago
Generic Ozempic Wave Could Redraw the Global GLP-1 Market

Key Takeaways Powered by lumidawealth.com India is set to become the first major market to see a large-scale rollout of generic semaglutide, with at least a dozen major drugmakers...

Read more
Next Post
China’s Bold Economic Moves: What You Need to Know Now

The 'Busan Freeze': How Trump Quietly Abandoned His Tough-on-China Playbook

White House, Washington DC

White House Sent Staff-Wide Email Warning Against Insider Trading on Iran War Bets

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

white paper with green line

Cautious Tone from BOJ: What It Means for Global Markets

September 20, 2024
A building with a sign on the side of it

Uniqlo Parent Fast Retailing Posts Strong Q1 Results, Driven by Global Expansion

January 9, 2025
red and blue light streaks

Investors Pull Billions from US Equity Funds Ahead of Earnings Reports

July 15, 2024

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Latest
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips AI demand Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC Semiconductor stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018